

Overview

- ICH S2 R1/US FDA, OECD, EFSA and EPA compliant genetic toxicology assays
- Flexible protocols combining multiple endpoints in *in vitro* and *in vivo* tests
- eCTD submission ready documents

Genetox Assays

- Ames assay including Prival modification (e.g., Azo dyes)
- *In vitro* flow cytometry-based micronucleus (MN) assay in human TK6 cells
- *In vitro* mutagenicity (TK^{+/−}) in human TK6 cells
- *In vitro* chromosomal aberrations in CHO cells
- *In vitro* Comet assay
- *In vivo* MN, Comet, and Pig-a mutation assays
- Integration of genotoxicity testing into subacute and subchronic *in vivo* assays
- Human stem cells as a model for predictive toxicology
- High throughput Comet assay development
- Assay development using gene signature panels
- Mode-of-action/risk assessment studies